These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7534919)

  • 21. Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis.
    Zhang L; Wang CY; Yang R; Shi J; Fu R; Chen L; Klocker H; Zhang J
    Urol Oncol; 2008; 26(6):634-40. PubMed ID: 18367130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
    Murphy GP; Barren RJ; Erickson SJ; Bowes VA; Wolfert RL; Bartsch G; Klocker H; Pointner J; Reissigl A; McLeod DG; Douglas T; Morgan T; Kenny GM; Ragde H; Boynton AL; Holmes EH
    Cancer; 1996 Aug; 78(4):809-18. PubMed ID: 8756376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared.
    Chan DW; Bruzek DJ; Oesterling JE; Rock RC; Walsh PC
    Clin Chem; 1987 Oct; 33(10):1916-20. PubMed ID: 2444361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer.
    Tarle M
    Anticancer Res; 1993; 13(3):769-77. PubMed ID: 7686362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer.
    Filella X; Molina R; Jo J; Umbert B; Bedini JL; Ballesta AM
    Tumour Biol; 1990; 11(6):289-94. PubMed ID: 1700860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
    Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
    J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia.
    Saedi MS; Hill TM; Kuus-Reichel K; Kumar A; Payne J; Mikolajczyk SD; Wolfert RL; Rittenhouse HG
    Clin Chem; 1998 Oct; 44(10):2115-9. PubMed ID: 9761243
    [TBL] [Abstract][Full Text] [Related]  

  • 28. alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer.
    Fukushima K; Satoh T; Baba S; Yamashita K
    Glycobiology; 2010 Jan; 20(4):452-60. PubMed ID: 20008118
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors.
    Tarle M; Kovacić K; Kastelan M
    Anticancer Res; 1993; 13(1):215-8. PubMed ID: 7682800
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
    Shannon BA; Cohen RJ; Garrett KL
    BJU Int; 2008 Feb; 101(4):429-35. PubMed ID: 17850358
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-specific antigen in prostatic cancer.
    Baron JC; Peyret C; Leroy M; Teillac P; Najean Y; Le Duc A
    Am J Clin Oncol; 1988; 11 Suppl 2():S75-6. PubMed ID: 2468279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presence of PSA auto-antibodies in men with prostate abnormalities (prostate cancer/benign prostatic hyperplasia/prostatitis).
    Lokant MT; Naz RK
    Andrologia; 2015 Apr; 47(3):328-32. PubMed ID: 24620795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific membrane antigen: current and future utility.
    Gregorakis AK; Holmes EH; Murphy GP
    Semin Urol Oncol; 1998 Feb; 16(1):2-12. PubMed ID: 9508077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [PSA in the staging and monitoring of cancer of the prostate].
    Gil Sanz MJ; Sanz Velez JI; Liedana Torres JM; Roncales Badal AL; Allepuz Losa C; Rioja Sanz LA
    Actas Urol Esp; 1991; 15(6):527-31. PubMed ID: 1724347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PSA-PSMA profiles and their impact on sera PSA levels and angiogenic activity in hyperplasia and human prostate cancer.
    Ben Jemaa A; Bouraoui Y; Sallami S; Banasr A; Nouira Y; Oueslati R
    Pathol Biol (Paris); 2014 Jun; 62(3):129-36. PubMed ID: 24745345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy.
    Thomas J; Gupta M; Grasso Y; Reddy CA; Heston WD; Zippe C; Dreicer R; Kupelian PA; Brainard J; Levin HS; Klein EA
    J Clin Oncol; 2002 Aug; 20(15):3213-8. PubMed ID: 12149293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
    Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
    Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients.
    Murphy GP; Maguire RT; Rogers B; Partin AW; Nelp WB; Troychak MJ; Ragde H; Kenny GM; Barren RJ; Bowes VA; Gregorakis AK; Holmes EH; Boynton AL
    Prostate; 1997 Dec; 33(4):281-5. PubMed ID: 9397201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progression of prostate cancer: diagnostic and prognostic utility of prostate-specific antigen, alpha2-macroglobulin, and their complexes.
    Kanoh Y; Ohtani N; Ohara T; Mashiko T; Ohtani S; Egawa S; Baba S; Ohtani H
    Oncol Rep; 2001; 8(3):515-9. PubMed ID: 11295072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients.
    Schmittgen TD; Teske S; Vessella RL; True LD; Zakrajsek BA
    Int J Cancer; 2003 Nov; 107(2):323-9. PubMed ID: 12949815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.